| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Flavonoids | 4 | 2021 | 109 | 1.910 |
Why?
|
| Receptors, Opioid | 7 | 2015 | 60 | 1.860 |
Why?
|
| Plant Extracts | 9 | 2021 | 122 | 1.730 |
Why?
|
| Fungicides, Industrial | 4 | 2014 | 7 | 1.360 |
Why?
|
| Alzheimer Disease | 6 | 2016 | 565 | 1.270 |
Why?
|
| Molecular Structure | 19 | 2016 | 397 | 1.150 |
Why?
|
| Aging | 9 | 2020 | 911 | 1.070 |
Why?
|
| Receptors, Cannabinoid | 3 | 2015 | 26 | 1.010 |
Why?
|
| Cognition | 2 | 2020 | 513 | 0.960 |
Why?
|
| Emericella | 2 | 2013 | 2 | 0.920 |
Why?
|
| Asteraceae | 3 | 2018 | 4 | 0.890 |
Why?
|
| Plant Leaves | 4 | 2018 | 49 | 0.870 |
Why?
|
| Cytisus | 2 | 2019 | 2 | 0.850 |
Why?
|
| Anxiety | 2 | 2016 | 422 | 0.840 |
Why?
|
| Antifungal Agents | 4 | 2017 | 108 | 0.800 |
Why?
|
| Eupenicillium | 2 | 2013 | 2 | 0.790 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2018 | 88 | 0.790 |
Why?
|
| Sesquiterpenes | 3 | 2018 | 41 | 0.780 |
Why?
|
| Mycophenolic Acid | 2 | 2013 | 62 | 0.770 |
Why?
|
| Monoamine Oxidase Inhibitors | 2 | 2017 | 30 | 0.750 |
Why?
|
| Trypanosoma brucei brucei | 3 | 2019 | 20 | 0.750 |
Why?
|
| Trypanocidal Agents | 1 | 2019 | 11 | 0.690 |
Why?
|
| Hypocreales | 3 | 2014 | 4 | 0.680 |
Why?
|
| Isocoumarins | 2 | 2016 | 2 | 0.680 |
Why?
|
| Hearing | 1 | 2020 | 133 | 0.670 |
Why?
|
| Microbial Sensitivity Tests | 11 | 2017 | 226 | 0.660 |
Why?
|
| Receptor, Cannabinoid, CB1 | 4 | 2018 | 68 | 0.660 |
Why?
|
| Memory | 1 | 2020 | 214 | 0.640 |
Why?
|
| Plants, Medicinal | 2 | 2017 | 43 | 0.630 |
Why?
|
| Monoamine Oxidase | 1 | 2017 | 26 | 0.610 |
Why?
|
| Memory Disorders | 3 | 2015 | 111 | 0.610 |
Why?
|
| Antioxidants | 2 | 2019 | 304 | 0.600 |
Why?
|
| Volunteers | 3 | 2004 | 30 | 0.600 |
Why?
|
| Antiprotozoal Agents | 4 | 2021 | 23 | 0.600 |
Why?
|
| Hearing Loss | 1 | 2020 | 154 | 0.590 |
Why?
|
| Cladosporium | 2 | 2016 | 2 | 0.590 |
Why?
|
| Attitude to Health | 2 | 2015 | 403 | 0.560 |
Why?
|
| Geriatrics | 2 | 2013 | 69 | 0.550 |
Why?
|
| Personal Satisfaction | 2 | 2016 | 123 | 0.550 |
Why?
|
| Mitragyna | 3 | 2018 | 7 | 0.540 |
Why?
|
| Receptor, Cannabinoid, CB2 | 3 | 2017 | 27 | 0.530 |
Why?
|
| Lamiaceae | 1 | 2015 | 3 | 0.520 |
Why?
|
| Alkaloids | 2 | 2016 | 40 | 0.510 |
Why?
|
| Benzofurans | 2 | 2013 | 21 | 0.510 |
Why?
|
| Zingiberaceae | 1 | 2015 | 1 | 0.510 |
Why?
|
| Anti-Infective Agents | 2 | 2013 | 166 | 0.490 |
Why?
|
| Curcuma | 1 | 2014 | 2 | 0.490 |
Why?
|
| Analgesics | 2 | 2015 | 118 | 0.480 |
Why?
|
| Humans | 69 | 2021 | 68618 | 0.470 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 179 | 0.460 |
Why?
|
| Chromones | 1 | 2013 | 33 | 0.460 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2013 | 1 | 0.460 |
Why?
|
| Resorcinols | 1 | 2013 | 8 | 0.450 |
Why?
|
| Lactones | 1 | 2013 | 64 | 0.430 |
Why?
|
| Public Policy | 1 | 2013 | 71 | 0.430 |
Why?
|
| Fatty Acids | 1 | 2013 | 222 | 0.420 |
Why?
|
| Magnetic Resonance Spectroscopy | 7 | 2015 | 346 | 0.420 |
Why?
|
| Cannabinoids | 3 | 2018 | 90 | 0.410 |
Why?
|
| Diospyros | 1 | 2011 | 1 | 0.400 |
Why?
|
| Eurotium | 1 | 2011 | 1 | 0.390 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 120 | 0.390 |
Why?
|
| Benzene Derivatives | 1 | 2011 | 12 | 0.390 |
Why?
|
| Models, Molecular | 5 | 2021 | 546 | 0.380 |
Why?
|
| Flavones | 3 | 2016 | 11 | 0.370 |
Why?
|
| Anti-Bacterial Agents | 3 | 2017 | 1026 | 0.360 |
Why?
|
| Molecular Docking Simulation | 4 | 2018 | 78 | 0.350 |
Why?
|
| Biomedical Research | 1 | 2013 | 310 | 0.350 |
Why?
|
| Molecular Conformation | 3 | 2018 | 128 | 0.350 |
Why?
|
| Hypericum | 2 | 2021 | 6 | 0.350 |
Why?
|
| Quercetin | 2 | 2021 | 16 | 0.340 |
Why?
|
| Aged | 31 | 2020 | 14862 | 0.340 |
Why?
|
| Health Surveys | 6 | 2016 | 489 | 0.340 |
Why?
|
| Secologanin Tryptamine Alkaloids | 2 | 2018 | 4 | 0.320 |
Why?
|
| Animals | 20 | 2021 | 20881 | 0.320 |
Why?
|
| HEK293 Cells | 5 | 2018 | 326 | 0.310 |
Why?
|
| Indole Alkaloids | 4 | 2014 | 18 | 0.310 |
Why?
|
| Stereoisomerism | 4 | 2018 | 169 | 0.300 |
Why?
|
| Crystallography, X-Ray | 3 | 2013 | 190 | 0.290 |
Why?
|
| Ovarian Neoplasms | 5 | 2021 | 267 | 0.280 |
Why?
|
| Middle Aged | 27 | 2020 | 21147 | 0.280 |
Why?
|
| Mass Spectrometry | 5 | 2017 | 284 | 0.270 |
Why?
|
| Social Behavior | 4 | 2004 | 164 | 0.270 |
Why?
|
| Rubiaceae | 2 | 2015 | 3 | 0.270 |
Why?
|
| Male | 35 | 2020 | 37321 | 0.260 |
Why?
|
| Female | 36 | 2021 | 38074 | 0.260 |
Why?
|
| Colletotrichum | 3 | 2014 | 3 | 0.260 |
Why?
|
| Protein Binding | 5 | 2015 | 1027 | 0.260 |
Why?
|
| Computers | 2 | 2003 | 63 | 0.250 |
Why?
|
| Regression Analysis | 4 | 2020 | 737 | 0.250 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2018 | 137 | 0.250 |
Why?
|
| Antineoplastic Agents | 5 | 2017 | 1070 | 0.240 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 4 | 2014 | 92 | 0.240 |
Why?
|
| Narcotic Antagonists | 2 | 2018 | 184 | 0.240 |
Why?
|
| Age Factors | 15 | 2015 | 1864 | 0.240 |
Why?
|
| Self-Assessment | 2 | 2011 | 69 | 0.240 |
Why?
|
| Ascomycota | 2 | 2014 | 8 | 0.230 |
Why?
|
| Cricetinae | 3 | 2013 | 262 | 0.230 |
Why?
|
| Naphthalenes | 2 | 2014 | 47 | 0.230 |
Why?
|
| Apoptosis | 3 | 2017 | 1641 | 0.230 |
Why?
|
| Trypanosoma | 2 | 2021 | 3 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2016 | 1745 | 0.220 |
Why?
|
| Quinolones | 2 | 2014 | 60 | 0.220 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 2 | 2021 | 12 | 0.220 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2017 | 73 | 0.220 |
Why?
|
| Glycosides | 2 | 2015 | 14 | 0.220 |
Why?
|
| Adult Children | 1 | 2003 | 7 | 0.220 |
Why?
|
| Saponins | 2 | 2015 | 13 | 0.220 |
Why?
|
| Schools, Pharmacy | 2 | 2014 | 36 | 0.210 |
Why?
|
| Chromatography, Thin Layer | 2 | 2015 | 52 | 0.210 |
Why?
|
| Triterpenes | 2 | 2015 | 40 | 0.210 |
Why?
|
| Aged, 80 and over | 11 | 2015 | 4848 | 0.210 |
Why?
|
| Georgia | 2 | 2013 | 161 | 0.200 |
Why?
|
| Camellia | 1 | 2021 | 2 | 0.200 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 498 | 0.200 |
Why?
|
| Trichodermin | 1 | 2021 | 1 | 0.190 |
Why?
|
| Kallikrein-Kinin System | 1 | 2021 | 18 | 0.190 |
Why?
|
| Mice | 7 | 2021 | 8474 | 0.190 |
Why?
|
| Labor Unions | 1 | 2001 | 3 | 0.190 |
Why?
|
| Genes, myc | 1 | 2021 | 26 | 0.190 |
Why?
|
| Christianity | 1 | 2001 | 16 | 0.190 |
Why?
|
| Organizations, Nonprofit | 1 | 2001 | 8 | 0.190 |
Why?
|
| Factor XII | 1 | 2021 | 96 | 0.190 |
Why?
|
| Phytochemicals | 1 | 2021 | 6 | 0.190 |
Why?
|
| Bradykinin | 2 | 2021 | 157 | 0.190 |
Why?
|
| Ligands | 3 | 2021 | 317 | 0.190 |
Why?
|
| Databases as Topic | 1 | 2020 | 49 | 0.180 |
Why?
|
| Antimalarials | 2 | 2017 | 71 | 0.180 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2021 | 109 | 0.180 |
Why?
|
| Internationality | 1 | 2020 | 74 | 0.180 |
Why?
|
| Hydroxybenzoates | 1 | 2019 | 9 | 0.180 |
Why?
|
| Adult | 21 | 2016 | 21403 | 0.180 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 42 | 0.170 |
Why?
|
| Enzyme Induction | 1 | 2019 | 119 | 0.170 |
Why?
|
| Insecticides | 3 | 2012 | 43 | 0.170 |
Why?
|
| Cell Proliferation | 5 | 2021 | 1174 | 0.170 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 371 | 0.170 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2019 | 201 | 0.170 |
Why?
|
| Fear | 2 | 1996 | 239 | 0.160 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 323 | 0.160 |
Why?
|
| Receptors, Opioid, delta | 2 | 2018 | 37 | 0.160 |
Why?
|
| MCF-7 Cells | 1 | 2018 | 80 | 0.160 |
Why?
|
| Cognition Disorders | 1 | 2001 | 342 | 0.160 |
Why?
|
| Algeria | 1 | 2017 | 1 | 0.150 |
Why?
|
| Leishmania donovani | 2 | 2015 | 19 | 0.150 |
Why?
|
| Social Class | 1 | 2018 | 127 | 0.150 |
Why?
|
| Singlet Oxygen | 1 | 2017 | 2 | 0.150 |
Why?
|
| Morphine | 1 | 2018 | 76 | 0.150 |
Why?
|
| Structure-Activity Relationship | 5 | 2018 | 420 | 0.150 |
Why?
|
| NF-kappa B | 1 | 2019 | 432 | 0.150 |
Why?
|
| Employment | 2 | 2014 | 154 | 0.150 |
Why?
|
| Biological Products | 1 | 2018 | 78 | 0.150 |
Why?
|
| Secondary Metabolism | 2 | 2015 | 2 | 0.150 |
Why?
|
| Terphenyl Compounds | 1 | 2017 | 1 | 0.150 |
Why?
|
| S Phase Cell Cycle Checkpoints | 1 | 2017 | 4 | 0.150 |
Why?
|
| Aspergillus | 1 | 2017 | 8 | 0.150 |
Why?
|
| Liliaceae | 2 | 2014 | 2 | 0.140 |
Why?
|
| Ecdysterone | 1 | 2016 | 1 | 0.140 |
Why?
|
| Atriplex | 1 | 2016 | 1 | 0.140 |
Why?
|
| Betaine | 1 | 2016 | 3 | 0.140 |
Why?
|
| Adenylyl Cyclases | 1 | 2017 | 94 | 0.140 |
Why?
|
| United States | 17 | 2014 | 7367 | 0.140 |
Why?
|
| Choline | 1 | 2016 | 14 | 0.140 |
Why?
|
| New England | 1 | 2016 | 16 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 756 | 0.140 |
Why?
|
| Herbicides | 1 | 2016 | 24 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2017 | 231 | 0.140 |
Why?
|
| Acetylcholine | 1 | 2016 | 64 | 0.140 |
Why?
|
| Seeds | 2 | 2011 | 23 | 0.140 |
Why?
|
| Eschscholzia | 1 | 2016 | 1 | 0.140 |
Why?
|
| Receptors, Steroid | 1 | 2016 | 13 | 0.140 |
Why?
|
| Caregivers | 3 | 1996 | 365 | 0.130 |
Why?
|
| Mental Health | 1 | 2018 | 278 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2016 | 62 | 0.130 |
Why?
|
| Research | 3 | 2012 | 214 | 0.130 |
Why?
|
| In Vitro Techniques | 2 | 2015 | 765 | 0.130 |
Why?
|
| Plasmodium falciparum | 4 | 2017 | 45 | 0.130 |
Why?
|
| Nelumbo | 1 | 2015 | 1 | 0.130 |
Why?
|
| Flowers | 1 | 2015 | 4 | 0.130 |
Why?
|
| Societies, Pharmaceutical | 2 | 2012 | 22 | 0.130 |
Why?
|
| Multivariate Analysis | 4 | 2003 | 1046 | 0.130 |
Why?
|
| Pakistan | 1 | 2015 | 3 | 0.130 |
Why?
|
| Plumbaginaceae | 1 | 2015 | 1 | 0.130 |
Why?
|
| Behavior, Animal | 1 | 2018 | 470 | 0.130 |
Why?
|
| Kinetics | 2 | 2014 | 1047 | 0.130 |
Why?
|
| Sociology | 1 | 1995 | 1 | 0.130 |
Why?
|
| Benzoquinones | 1 | 2015 | 13 | 0.130 |
Why?
|
| Cricetulus | 2 | 2014 | 98 | 0.130 |
Why?
|
| Family | 2 | 1996 | 293 | 0.120 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 230 | 0.120 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2012 | 67 | 0.120 |
Why?
|
| Phenols | 1 | 2015 | 73 | 0.120 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2014 | 4 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2014 | 9 | 0.120 |
Why?
|
| Guanidines | 1 | 2014 | 32 | 0.120 |
Why?
|
| Receptors, Neuropeptide | 1 | 2014 | 22 | 0.120 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 1851 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2017 | 659 | 0.120 |
Why?
|
| Salicylates | 1 | 2014 | 22 | 0.120 |
Why?
|
| Cyclohexanones | 1 | 2014 | 9 | 0.120 |
Why?
|
| Occupations | 1 | 2014 | 27 | 0.120 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 34 | 0.120 |
Why?
|
| Leukemia | 2 | 2012 | 117 | 0.120 |
Why?
|
| Benzhydryl Compounds | 1 | 2014 | 62 | 0.120 |
Why?
|
| Piperidines | 1 | 2014 | 123 | 0.120 |
Why?
|
| Mycelium | 1 | 2013 | 1 | 0.120 |
Why?
|
| Linoleic Acid | 1 | 2013 | 13 | 0.120 |
Why?
|
| Faculty | 1 | 2014 | 56 | 0.110 |
Why?
|
| Romania | 1 | 2013 | 11 | 0.110 |
Why?
|
| Carboxylic Acids | 1 | 2013 | 24 | 0.110 |
Why?
|
| Cisplatin | 1 | 2014 | 192 | 0.110 |
Why?
|
| Chromatography, Gas | 2 | 2012 | 31 | 0.110 |
Why?
|
| Cannabis | 1 | 2015 | 115 | 0.110 |
Why?
|
| Palmitic Acid | 1 | 2013 | 51 | 0.110 |
Why?
|
| Aniline Compounds | 1 | 2013 | 52 | 0.110 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 28 | 0.110 |
Why?
|
| Plant Diseases | 1 | 2013 | 10 | 0.110 |
Why?
|
| Aspergillus fumigatus | 2 | 2014 | 27 | 0.110 |
Why?
|
| Hydrocodone | 1 | 2013 | 5 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 71 | 0.110 |
Why?
|
| Thiophenes | 1 | 2013 | 76 | 0.110 |
Why?
|
| Adenosine Triphosphate | 1 | 2014 | 314 | 0.110 |
Why?
|
| Anthraquinones | 1 | 2013 | 18 | 0.110 |
Why?
|
| Perception | 1 | 2014 | 189 | 0.110 |
Why?
|
| Frail Elderly | 1 | 1993 | 31 | 0.110 |
Why?
|
| Organizations | 3 | 1977 | 16 | 0.110 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2012 | 18 | 0.110 |
Why?
|
| Binding Sites | 3 | 2021 | 631 | 0.100 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2014 | 133 | 0.100 |
Why?
|
| Home Care Services | 1 | 1993 | 84 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 332 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 219 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 183 | 0.100 |
Why?
|
| Mitosporic Fungi | 1 | 2011 | 2 | 0.100 |
Why?
|
| Confusion | 1 | 1992 | 20 | 0.100 |
Why?
|
| Plant Oils | 1 | 2012 | 31 | 0.100 |
Why?
|
| Transportation | 1 | 1992 | 21 | 0.100 |
Why?
|
| Plant Roots | 1 | 2011 | 22 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 150 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2014 | 331 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 147 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2013 | 447 | 0.100 |
Why?
|
| Community Health Services | 1 | 1993 | 141 | 0.100 |
Why?
|
| Pain | 1 | 2015 | 472 | 0.100 |
Why?
|
| Arachis | 1 | 2011 | 8 | 0.100 |
Why?
|
| Geriatric Assessment | 1 | 1992 | 107 | 0.100 |
Why?
|
| Self Concept | 1 | 1992 | 132 | 0.100 |
Why?
|
| Escherichia coli | 2 | 2014 | 368 | 0.100 |
Why?
|
| MAP Kinase Signaling System | 1 | 2012 | 247 | 0.090 |
Why?
|
| Cell Line | 2 | 2013 | 1752 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 240 | 0.090 |
Why?
|
| Quality of Life | 2 | 2018 | 1515 | 0.090 |
Why?
|
| Health Services Needs and Demand | 2 | 1989 | 149 | 0.090 |
Why?
|
| Students, Pharmacy | 1 | 2011 | 79 | 0.090 |
Why?
|
| Rats | 7 | 2018 | 5300 | 0.090 |
Why?
|
| Attitude | 2 | 1983 | 121 | 0.090 |
Why?
|
| Sex Factors | 9 | 2000 | 1266 | 0.090 |
Why?
|
| Stilbenes | 1 | 2011 | 57 | 0.090 |
Why?
|
| Education, Pharmacy | 1 | 2011 | 102 | 0.090 |
Why?
|
| Depression | 1 | 2016 | 943 | 0.080 |
Why?
|
| Hypertension | 1 | 2018 | 1535 | 0.080 |
Why?
|
| Health Services for the Aged | 1 | 1989 | 21 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 2018 | 381 | 0.080 |
Why?
|
| Cryptococcus neoformans | 1 | 2008 | 24 | 0.080 |
Why?
|
| Candida albicans | 1 | 2008 | 39 | 0.080 |
Why?
|
| Rural Health | 1 | 1989 | 66 | 0.080 |
Why?
|
| Adolescent | 10 | 2004 | 8912 | 0.080 |
Why?
|
| Arthritis, Experimental | 2 | 2006 | 38 | 0.080 |
Why?
|
| Edema | 2 | 2006 | 66 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 1988 | 117 | 0.080 |
Why?
|
| Health Services Research | 1 | 1988 | 209 | 0.070 |
Why?
|
| Caproates | 1 | 2006 | 3 | 0.070 |
Why?
|
| Demography | 2 | 2003 | 279 | 0.070 |
Why?
|
| Esters | 1 | 2006 | 22 | 0.070 |
Why?
|
| Cell Survival | 3 | 2021 | 901 | 0.070 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2006 | 29 | 0.070 |
Why?
|
| Triticum | 3 | 2000 | 14 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2003 | 1553 | 0.070 |
Why?
|
| Neuropeptides | 1 | 2006 | 106 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2017 | 111 | 0.060 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2005 | 78 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2003 | 955 | 0.060 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 2 | 2015 | 85 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 1465 | 0.060 |
Why?
|
| CHO Cells | 2 | 2014 | 161 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2004 | 1054 | 0.060 |
Why?
|
| Women's Rights | 1 | 1983 | 5 | 0.050 |
Why?
|
| HL-60 Cells | 2 | 2013 | 50 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2003 | 31 | 0.050 |
Why?
|
| Emotions | 1 | 2004 | 244 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2003 | 2279 | 0.050 |
Why?
|
| Cell Line, Transformed | 2 | 2017 | 100 | 0.050 |
Why?
|
| Advisory Committees | 2 | 2012 | 73 | 0.050 |
Why?
|
| Fungi | 2 | 2017 | 27 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2018 | 2083 | 0.050 |
Why?
|
| Mycotoxins | 1 | 2001 | 5 | 0.050 |
Why?
|
| Plant Growth Regulators | 1 | 2000 | 2 | 0.050 |
Why?
|
| Penicillium | 1 | 2000 | 3 | 0.050 |
Why?
|
| Protozoan Proteins | 1 | 2021 | 25 | 0.050 |
Why?
|
| Conserved Sequence | 1 | 2021 | 67 | 0.050 |
Why?
|
| Urban Population | 3 | 1992 | 255 | 0.050 |
Why?
|
| Spiro Compounds | 1 | 2000 | 14 | 0.050 |
Why?
|
| Decision Making | 1 | 2004 | 410 | 0.050 |
Why?
|
| Gap Junctions | 1 | 2001 | 29 | 0.050 |
Why?
|
| Diterpenes | 1 | 2000 | 42 | 0.050 |
Why?
|
| Trichoderma | 1 | 2000 | 1 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2021 | 60 | 0.050 |
Why?
|
| Protein Structure, Secondary | 1 | 2021 | 136 | 0.050 |
Why?
|
| Educational Status | 2 | 2000 | 273 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 304 | 0.040 |
Why?
|
| Abortion, Legal | 1 | 1980 | 3 | 0.040 |
Why?
|
| Rosales | 1 | 1999 | 2 | 0.040 |
Why?
|
| Marital Status | 1 | 2000 | 65 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 329 | 0.040 |
Why?
|
| Indoles | 1 | 2001 | 146 | 0.040 |
Why?
|
| Bacteria | 2 | 2017 | 193 | 0.040 |
Why?
|
| Residence Characteristics | 2 | 1989 | 252 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2017 | 431 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2021 | 312 | 0.040 |
Why?
|
| Self-Help Groups | 2 | 1977 | 38 | 0.040 |
Why?
|
| Water | 1 | 2021 | 230 | 0.040 |
Why?
|
| Life Style | 2 | 2018 | 338 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2003 | 786 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2014 | 2800 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 1993 | 319 | 0.040 |
Why?
|
| Databases, Pharmaceutical | 1 | 2018 | 2 | 0.040 |
Why?
|
| Drug Inverse Agonism | 1 | 2018 | 7 | 0.040 |
Why?
|
| Gastrointestinal Transit | 1 | 2018 | 16 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2021 | 1083 | 0.040 |
Why?
|
| Radioligand Assay | 1 | 2018 | 109 | 0.040 |
Why?
|
| Crime | 1 | 1979 | 53 | 0.040 |
Why?
|
| Health Status | 2 | 2000 | 429 | 0.040 |
Why?
|
| Psychology | 1 | 2018 | 36 | 0.040 |
Why?
|
| Benzene | 1 | 1998 | 9 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 215 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 1998 | 50 | 0.040 |
Why?
|
| Astrocytes | 1 | 2001 | 270 | 0.040 |
Why?
|
| Naloxone | 1 | 2018 | 56 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2015 | 328 | 0.040 |
Why?
|
| Leishmania major | 1 | 2017 | 1 | 0.040 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2017 | 8 | 0.040 |
Why?
|
| Photochemical Processes | 1 | 2017 | 10 | 0.040 |
Why?
|
| Acetates | 1 | 1998 | 74 | 0.040 |
Why?
|
| Receptors, Opioid, mu | 1 | 2018 | 70 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 508 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2017 | 12 | 0.040 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 7 | 0.040 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 14 | 0.040 |
Why?
|
| Automobile Driving | 2 | 1975 | 88 | 0.040 |
Why?
|
| Rural Population | 2 | 1992 | 398 | 0.040 |
Why?
|
| El Salvador | 1 | 2016 | 8 | 0.040 |
Why?
|
| Happiness | 1 | 1976 | 5 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2017 | 93 | 0.030 |
Why?
|
| Naltrexone | 1 | 2018 | 195 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 231 | 0.030 |
Why?
|
| Leisure Activities | 1 | 1976 | 22 | 0.030 |
Why?
|
| Self Administration | 1 | 2018 | 419 | 0.030 |
Why?
|
| Ovary | 1 | 2017 | 99 | 0.030 |
Why?
|
| Berberine Alkaloids | 1 | 2016 | 1 | 0.030 |
Why?
|
| Benzophenanthridines | 1 | 2016 | 5 | 0.030 |
Why?
|
| Dioxoles | 1 | 2016 | 8 | 0.030 |
Why?
|
| Herb-Drug Interactions | 1 | 2016 | 5 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2016 | 99 | 0.030 |
Why?
|
| Madin Darby Canine Kidney Cells | 1 | 2016 | 22 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1992 | 219 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2016 | 68 | 0.030 |
Why?
|
| Social Environment | 2 | 1996 | 182 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2673 | 0.030 |
Why?
|
| DNA Damage | 1 | 2017 | 190 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2017 | 362 | 0.030 |
Why?
|
| Family Characteristics | 1 | 1996 | 44 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 1996 | 68 | 0.030 |
Why?
|
| Plant Components, Aerial | 1 | 2015 | 2 | 0.030 |
Why?
|
| Candida glabrata | 1 | 2015 | 3 | 0.030 |
Why?
|
| Mississippi | 1 | 2015 | 11 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2015 | 59 | 0.030 |
Why?
|
| Income | 2 | 1993 | 167 | 0.030 |
Why?
|
| Dogs | 1 | 2016 | 490 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2018 | 706 | 0.030 |
Why?
|
| Candida | 1 | 2014 | 15 | 0.030 |
Why?
|
| Hydrogen Bonding | 1 | 2014 | 67 | 0.030 |
Why?
|
| Mycobacterium avium Complex | 1 | 2014 | 16 | 0.030 |
Why?
|
| Freedom | 1 | 2014 | 9 | 0.030 |
Why?
|
| Dronabinol | 1 | 2015 | 84 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 196 | 0.030 |
Why?
|
| Job Description | 1 | 2014 | 23 | 0.030 |
Why?
|
| Circular Dichroism | 1 | 2014 | 99 | 0.030 |
Why?
|
| tau Proteins | 1 | 2014 | 61 | 0.030 |
Why?
|
| Organizational Innovation | 1 | 2014 | 55 | 0.030 |
Why?
|
| History, 20th Century | 1 | 1995 | 248 | 0.030 |
Why?
|
| Organizational Affiliation | 1 | 1974 | 8 | 0.030 |
Why?
|
| Career Mobility | 1 | 2014 | 34 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2014 | 42 | 0.030 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 298 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 1974 | 38 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 219 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 209 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2013 | 7 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 322 | 0.030 |
Why?
|
| Travel | 1 | 1974 | 38 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2550 | 0.030 |
Why?
|
| K562 Cells | 1 | 2013 | 44 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 489 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 45 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2014 | 98 | 0.030 |
Why?
|
| Cyclization | 1 | 2013 | 14 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 852 | 0.030 |
Why?
|
| Annual Reports as Topic | 1 | 2012 | 12 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 710 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 379 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 434 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 954 | 0.030 |
Why?
|
| Monoterpenes | 1 | 2012 | 8 | 0.030 |
Why?
|
| Aedes | 1 | 2012 | 5 | 0.030 |
Why?
|
| Entrepreneurship | 1 | 2011 | 5 | 0.030 |
Why?
|
| Consumer Advocacy | 1 | 2011 | 6 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 140 | 0.030 |
Why?
|
| Temperature | 1 | 2013 | 341 | 0.030 |
Why?
|
| Neoplasms | 2 | 1974 | 1667 | 0.030 |
Why?
|
| Caspases | 1 | 2012 | 194 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 134 | 0.030 |
Why?
|
| Inflammation | 1 | 1998 | 1030 | 0.030 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 81 | 0.020 |
Why?
|
| Motor Activity | 1 | 2015 | 621 | 0.020 |
Why?
|
| Policy Making | 1 | 2011 | 51 | 0.020 |
Why?
|
| Plants | 1 | 2011 | 26 | 0.020 |
Why?
|
| Professional Competence | 1 | 2011 | 100 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2012 | 791 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2011 | 199 | 0.020 |
Why?
|
| Research Design | 1 | 1995 | 729 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2005 | 1200 | 0.020 |
Why?
|
| Leadership | 1 | 2011 | 136 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2014 | 1664 | 0.020 |
Why?
|
| Community Health Centers | 1 | 1990 | 26 | 0.020 |
Why?
|
| Home Nursing | 1 | 1989 | 8 | 0.020 |
Why?
|
| Population Growth | 1 | 1989 | 6 | 0.020 |
Why?
|
| Uterine Neoplasms | 3 | 1974 | 99 | 0.020 |
Why?
|
| Homes for the Aged | 1 | 1989 | 16 | 0.020 |
Why?
|
| Time Factors | 2 | 2016 | 4655 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 234 | 0.020 |
Why?
|
| Suburban Population | 1 | 1988 | 7 | 0.020 |
Why?
|
| Nursing Homes | 1 | 1989 | 54 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5731 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 2791 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 575 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 2689 | 0.020 |
Why?
|
| Group II Phospholipases A2 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 3 | 1973 | 17 | 0.020 |
Why?
|
| Cyclooxygenase 1 | 1 | 2006 | 29 | 0.020 |
Why?
|
| Phospholipases A | 1 | 2006 | 41 | 0.020 |
Why?
|
| Substance P | 1 | 2006 | 39 | 0.020 |
Why?
|
| Sciatic Nerve | 1 | 2006 | 26 | 0.020 |
Why?
|
| Cohort Studies | 1 | 1993 | 2358 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 63 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 160 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 1988 | 1040 | 0.020 |
Why?
|
| Cytokinesis | 1 | 2005 | 1 | 0.020 |
Why?
|
| Reaction Time | 2 | 1998 | 170 | 0.020 |
Why?
|
| Population Surveillance | 2 | 1980 | 285 | 0.020 |
Why?
|
| Automobiles | 2 | 1975 | 26 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2005 | 331 | 0.010 |
Why?
|
| Gender Identity | 1 | 1983 | 47 | 0.010 |
Why?
|
| Pregnancy | 2 | 1980 | 2334 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 1974 | 300 | 0.010 |
Why?
|
| Dieldrin | 1 | 2001 | 1 | 0.010 |
Why?
|
| Endosulfan | 1 | 2001 | 2 | 0.010 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2000 | 25 | 0.010 |
Why?
|
| Fermentation | 1 | 2000 | 20 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2001 | 104 | 0.010 |
Why?
|
| Cell Communication | 1 | 2001 | 116 | 0.010 |
Why?
|
| Interpersonal Relations | 2 | 1989 | 209 | 0.010 |
Why?
|
| Connexin 43 | 1 | 2001 | 62 | 0.010 |
Why?
|
| Social Conformity | 1 | 1980 | 2 | 0.010 |
Why?
|
| Legislation as Topic | 1 | 1980 | 6 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1118 | 0.010 |
Why?
|
| Archives | 1 | 1979 | 1 | 0.010 |
Why?
|
| Biological Assay | 1 | 1999 | 88 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1974 | 629 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2001 | 205 | 0.010 |
Why?
|
| Child | 5 | 1974 | 6405 | 0.010 |
Why?
|
| Carrageenan | 1 | 1998 | 7 | 0.010 |
Why?
|
| North Carolina | 1 | 1979 | 224 | 0.010 |
Why?
|
| Mixed Function Oxygenases | 1 | 1998 | 35 | 0.010 |
Why?
|
| Safety | 1 | 1979 | 145 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1998 | 73 | 0.010 |
Why?
|
| Foot | 1 | 1998 | 66 | 0.010 |
Why?
|
| Serotonin | 1 | 1998 | 144 | 0.010 |
Why?
|
| Universities | 1 | 1979 | 191 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 415 | 0.010 |
Why?
|
| Data Collection | 1 | 1979 | 420 | 0.010 |
Why?
|
| Statistics as Topic | 2 | 1988 | 219 | 0.010 |
Why?
|
| Carcinoma in Situ | 2 | 1974 | 47 | 0.010 |
Why?
|
| Child, Preschool | 4 | 1974 | 3187 | 0.010 |
Why?
|
| Infant | 3 | 1972 | 2891 | 0.010 |
Why?
|
| Intestinal Neoplasms | 1 | 1974 | 30 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 1974 | 83 | 0.010 |
Why?
|
| Geography | 1 | 1974 | 80 | 0.010 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1974 | 40 | 0.010 |
Why?
|
| Endometrium | 1 | 1974 | 31 | 0.010 |
Why?
|
| Choriocarcinoma | 1 | 1974 | 7 | 0.010 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 1974 | 6 | 0.010 |
Why?
|
| Corpus Luteum | 1 | 1974 | 8 | 0.010 |
Why?
|
| Placenta Diseases | 1 | 1974 | 5 | 0.010 |
Why?
|
| Vaginal Neoplasms | 1 | 1974 | 21 | 0.010 |
Why?
|
| Vulvar Neoplasms | 1 | 1974 | 24 | 0.010 |
Why?
|
| Health | 1 | 1974 | 26 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1974 | 46 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1974 | 109 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1974 | 1536 | 0.010 |
Why?
|
| Sarcoma | 1 | 1974 | 70 | 0.010 |
Why?
|
| Health Expenditures | 1 | 1974 | 170 | 0.010 |
Why?
|
| Puerto Rico | 1 | 1972 | 31 | 0.010 |
Why?
|
| Stomach Neoplasms | 1 | 1972 | 64 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 1972 | 75 | 0.010 |
Why?
|
| Length of Stay | 1 | 1974 | 780 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1974 | 475 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 1972 | 150 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1972 | 138 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1974 | 375 | 0.010 |
Why?
|
| Melanoma | 1 | 1974 | 335 | 0.010 |
Why?
|
| Marriage | 1 | 1989 | 30 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1972 | 299 | 0.010 |
Why?
|
| Hospitalization | 1 | 1974 | 978 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1972 | 332 | 0.000 |
Why?
|
| Hearing Disorders | 1 | 1988 | 23 | 0.000 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1967 | 9 | 0.000 |
Why?
|
| Leukemia, Myeloid | 1 | 1967 | 39 | 0.000 |
Why?
|
| Vision Disorders | 1 | 1988 | 94 | 0.000 |
Why?
|
| Prognosis | 2 | 1971 | 2093 | 0.000 |
Why?
|
| Acute Disease | 1 | 1967 | 658 | 0.000 |
Why?
|
| Prostatic Neoplasms | 1 | 1972 | 778 | 0.000 |
Why?
|
| Lung Neoplasms | 1 | 1972 | 1173 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1967 | 1330 | 0.000 |
Why?
|
| Bone Marrow Examination | 2 | 1973 | 6 | 0.000 |
Why?
|
| Leukocyte Count | 2 | 1973 | 94 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1967 | 2455 | 0.000 |
Why?
|
| Connecticut | 1 | 1974 | 13 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1973 | 51 | 0.000 |
Why?
|
| Carcinoma | 1 | 1974 | 215 | 0.000 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1971 | 185 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1973 | 3259 | 0.000 |
Why?
|